SCHEMBL1114730

SCHEMBL1114730

CC1NCCNCCNCCN(C)C1(C)C

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.34
SOS2 Q07890 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL576793 1.00 SOS1 (0.34) SOS1SOS2
SCHEMBL1907294 0.87 SOS1 (0.30) SOS1SOS2
Ammonia Solution, Strong SCHEMBL28132440 0.85
SCHEMBL8005344 0.85
SCHEMBL457018 0.83 CXCR4 (0.36)
SCHEMBL28213926 0.78
SCHEMBL9241450 0.78 SOS1 (0.33) SOS1SOS2
Formamide SCHEMBL29115926 0.77
SCHEMBL28144701 0.76 CXCR4 (0.32)
SCHEMBL8219562 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3383441-A1 FORMULATIONS COMPRISING A COMBINATION OF MRI CONTRAST AGENTS GE Healthcare AS (NO) 2018-10-10 EP claimed
WO-2017093336-A1 FORMULATIONS COMPRISING A COMBINATION OF MRI CONTRAST AGENTS GE HEALTHCARE AS (NO) 2017-06-08 WO claimed
EP-2661473-A1 ANTISKINNING COMPOSITIONS OMG UK Technology Limited (GB) 2013-11-13 EP claimed
WO-2012093250-A1 ANTISKINNING COMPOSITIONS OMG ADDITIVES LIMITED (GB) 2012-07-12 WO claimed
EP-0998466-A1 A PROCESS FOR THE PREPARATION OF TETRAAZAMACROCYCLES BRACCO IMAGING S.p.A. (IT) 2000-05-10 EP claimed
WO-1999005128-A1 A PROCESS FOR THE PREPARATION OF TETRAAZAMACROCYCLES BRACCO S.P.A. (IT) 1999-02-04 WO claimed
CN-114555132-A Method for producing radiometal-labeled antibody 日本医事物理股份有限公司 2022-05-27 CN disclosed
EP-2279190-A1 COMPOUNDS COMPRISING PARAMAGNETIC CHELATES ARRANGED AROUND A CENTRAL CORE AND THEIR USE IN MAGNETO RESONANCE IMAGING AND SPECTROSCOPY GE HEALTHCARE AS (NO) 2011-02-02 EP disclosed
WO-2009127715-A1 COMPOUNDS COMPRISING PARAMAGNETIC CHELATES ARRANGED AROUND A CENTRAL CORE AND THEIR USE IN MAGNETO RESONANCE IMAGING AND SPECTROSCOPY GE HEALTHCARE AS (NO) 2009-10-22 WO disclosed
EP-1960393-A1 MULTIMERIC MAGENTIC RESONANCE CONTRAST AGENTS GE Healthcare AS (NO) 2008-08-27 EP disclosed
WO-2007111514-A1 CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY CONSISTING OF A CYCLIC OLIGOAMID CORE OF 3 TO 4 IDENTICAL MONOMER UNITS WITH 3 TO 4 PARAMAGNETIC CHELATE SIDE CHAINS GE HEALTHCARE AS (NO) 2007-10-04 WO disclosed
WO-2007064227-A1 MULTIMERIC MAGENTIC RESONANCE CONTRAST AGENTS GE HEALTHCARE AS (NO) 2007-06-07 WO disclosed
US-7164016-B2 Macrocyclic metal complexes and their use for the production of conjugates with biomolecules SCHERING AG (DE) 2007-01-16 US disclosed
US-20030108486-A1 Macrocyclic metal complexes and their use for the production of conjugates with biomolecules SCHERING AG (DE) 2003-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030108486-A1 Macrocyclic metal complexes and their use for the production of conjugates with biomolecules CA13, MPI, CA14 SOS1 4823/4885SOS2 4792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.